A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease. Status: Recruiting Sponsor: Cognition Therapeutics More info
A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-week Safety and Efficacy trial of ANAVEX2-73 for the Treatment of Early Alzheimer’s disease (AD) Status: Recruiting Sponsor: ANAVEX Australia Pty Limited More info